Le Lézard
Classified in: Health
Subjects: PDT, SVY, BFA

A Fundamental Scientific Study on The Effect of Synthesit Iron With Vitamin B6 Has Been Published


The year 2024 showed a great start for Synthesit Swiss SA. 

GENEVA, Feb. 27, 2024 /PRNewswire/ -- On 15. January 2024 Frontiers in Nutrition, one of the most respected scientific Swiss journals, published a research article on the long term effect of iron supplementation combined with vitamin B6 on the maximum oxygen consumption and energy production. Iron is an essential micronutrient. It plays a vital part in many biological processes. The research shows that iron supplementation increases ATP synthesis in muscle mitochondria by more than 60% and brain mitochondria by more than 30%, and also increases maximum oxygen consumption by more than 10%. 

Furthermore, a case report cited in "Acta Medica Martiniana", a European scientific journal, depicts a clinical case of a patient with pancreatic cancer. It shows how Synthesit alleviates intoxication during chemotherapy. 

Synthesit Swiss SA is engaged in recreating natural processes in the laboratory. In 2019 it created a new biogenic iron, called SYNTHESIT. This iron-based mineral portrays completely different principles of action, in comparison to regular iron preparations. Synthesit activates the body's internal resources. Find the original research articles here: 

https://www.frontiersin.org/articles/10.3389/fnut.2023.1335187/full
https://sciendo.com/article/10.2478/acm-2023-0014
 

Contact:
Lisa Petzold
Synthesit Swiss SA
+ 41225330507
373530@email4pr.com

SOURCE Synthesit Swiss SA


These press releases may also interest you

at 02:05
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

at 02:05
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 01:00
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...



News published on and distributed by: